Search

Displaying results 9621 - 9630 of 10000 in total
  1. Drug

    Cadmium

    go.drugbank.com/drugs/DB14085
    Experimental

    An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.

  2. Drug

    Foscenvivint

    go.drugbank.com/drugs/DB15034
    Investigational

    PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).

  3. Drug

    TP-271

    go.drugbank.com/drugs/DB15040
    Investigational

    TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).

  4. Drug

    25-desacetylrifapentine

    go.drugbank.com/drugs/DB15213
    Investigational

    25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).

  5. Drug

    AN2898

    go.drugbank.com/drugs/DB16039
    Investigational

    AN2898 is under investigation in clinical trial NCT01301508 (Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-moderate Atopic Dermatitis).

  6. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  7. Drug

    GED-0507-34-Levo

    go.drugbank.com/drugs/DB16109
    Investigational

    GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).

  8. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  9. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    It is currently being investigated in clinical trials for the treatment of cancer.

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]